TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Daré Bioscience ( (DARE) ) has shared an announcement.
Daré Bioscience, Inc. announced that it will use a corporate presentation dated September 2, 2025, in various meetings with securities market participants. The presentation will be available on the company’s website in the ‘Investors’ section, indicating a strategic move to engage with stakeholders and potentially enhance its market presence.
The most recent analyst rating on (DARE) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Daré Bioscience stock, see the DARE Stock Forecast page.
Spark’s Take on DARE Stock
According to Spark, TipRanks’ AI Analyst, DARE is a Neutral.
Daré Bioscience’s overall stock score is primarily impacted by its financial instability, with persistent unprofitability and negative equity posing significant risks. While the earnings call provided an optimistic outlook with strategic initiatives and upcoming product launches, the technical analysis and valuation metrics reflect a bearish sentiment and unattractive valuation. The company’s future growth potential hinges on successful execution of its dual-path strategy and product commercialization.
To see Spark’s full report on DARE stock, click here.
More about Daré Bioscience
Average Trading Volume: 1,569,056
Technical Sentiment Signal: Strong Sell
Current Market Cap: $27.23M
See more insights into DARE stock on TipRanks’ Stock Analysis page.